Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non‐brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1375 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Michael Babcock und 8 weiteren Autor:innen. Beteiligte Einrichtung: AceLink Therapeutics, Newark, CA, USA. Hauptthemen laut MEDLINE: Gaucher Disease, Glucosyltransferases, Enzyme Inhibitors, Fabry Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glycosphingolipid (GSL) storage diseases are caused by deficiencies in the enzymes that metabolize different GSLs in the lysosome. Glucosylceramide synthase (GCS) inhibitors reduce GSL production and have potential to treat multiple GSL storage diseases. AL01211 is a potent, oral GCS inhibitor being developed for the treatment of Type 1 Gaucher disease and Fabry disease. AL01211 has minimal central nervous system penetration, allowing for treatment of peripheral organs without risking CNS‐associated adverse effects. AL01211 was evaluated in a Phase 1 healthy volunteer study with single ascending dose (SAD) and multiple ascending dose (MAD) arms, to determine safety, pharmacokinetics including food effect, and pharmacodynamic effects on associated GSLs. In the SAD arm, AL01211 showed a Tmax of approximately 3.5 hours, mean clearance (CL/F) of 130.1 L/h, and t 1/2 of 39.3 hours. Consuming a high‐fat meal prior to dose administration reduced exposures 3.5‐5.5‐fold, indicating a food effect. In the MAD arm, AL01211 had an approximately 2‐fold accumulation, reaching steady‐state levels by 10 days. Increasing exposure inversely correlated with a decrease in GSL with plasma glucosylceramide and globotriacylceramide reduction from baseline levels, reaching 78% and 52% by day 14, respectively. AL01211 was generally well‐tolerated with no AL01211 associated serious adverse events, thus supporting its further clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AceLink Therapeutics, Newark, CA, USA.
- BioMarin Pharmaceutical, San Rafael, CA, USA.
- Nucleus Network, Melbourne, Victoria, Australia.
Zitieren
APA
Babcock, M., Zheng, J., Gail Shurr, J., Li, L., Wang, B., Huertas, P., Ryan, P. J., Shen, Y., & Garovoy, M. (2024). Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non‐brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1375
Vancouver
Babcock M, Zheng J, Gail Shurr J, Li L, Wang B, Huertas P, et al. Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non‐brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1375
BibTeX
@article{Babcock2024,
author = {Babcock, Michael and Zheng, Jianhong and Gail Shurr, Jessica and Li, Li and Wang, Bing and Huertas, Pedro and Ryan, Philip John and Shen, Yuqiao and Garovoy, Marvin},
title = {Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non‐brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1375}
}
EUVIMED